Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study

SelfRugger · 2026-04-07T13:45:47+00:00

Arcellx (ACLX) presents promising lab study data, suggesting its CAR-T therapy could outperform competitors in terms of safety. While analysts differ on ratings and price targets, the company's potential in cancer immunotherapy remains notable.

SelfRugger

2026-04-07 13:45:47

Abstract generation in progress

Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study

Muhammad Ali Khalid

Tue, February 17, 2026 at 3:03 AM GMT+9 2 min read

In this article:

ACLX

-0.22%

Arcellx Incorporated (NASDAQ:ACLX) is one of 17 biotechnology stocks with more than 50% upside.

On February 12, Qize Ding from Rothschild & Co Redburn downgraded the rating on Arcellx Incorporated (NASDAQ:ACLX) from Buy to Neutral. In the process, he also reduced the price target from $113 to $82, which still yields a revised upside potential of almost 20%. Ding’s views are based on his conservative stance on the company’s CAR-T cell therapy class amid rising competition across larger markets in other modalities.

On February 9, Stifel analyst Stephen Willey reaffirmed his Buy rating on Arcellx Incorporated (NASDAQ:ACLX), with a $127 price target. His forecast leads to an upside potential of 85% from the current level.

Willey’s rating came after the company presented new laboratory study data at the TANDEM meeting. He highlighted that the findings support anito-cel’s potentially leading safety profile, showing lower unintended immune activity and fewer off-target effects than rival CAR-T treatments. The analyst also pointed to differences versus cilta-cel (Carvykti) and ide-cel (Abecma), suggesting its off-target interactions could be linked to severe delayed side effects seen in clinical use. Moreover, Willey believes the data strengthens anito-cel’s positioning as a potentially best-in-class therapy and continues to view the stock as a “core SMid-cap holding.”

Arcellx Incorporated (NASDAQ:ACLX) develops advanced immunotherapies for cancer patients and individuals with other incurable conditions. The company leverages its proprietary D-Domain technology to develop more effective treatments that target AML, multiple myeloma, and other malignancies. The current pipeline includes the development of ACLX-001 and ACLX-002, which target BCMA in rrMM and CD123 in AML/MDS.

While we acknowledge the potential of ACLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.